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The bleeding patterns of severe von Willebrand’s disease (VWD) adversely affect quality of life, 
and may be life threatening. There is a presumed role for prophylaxis with VWF-containing 
concentrates, but data are scarce. The von Willebrand Disease Prophylaxis Network (VWD PN) 
was formed to investigate the role of prophylaxis in clinically severe VWD that is not responsive 
to other treatment(s). Using a retrospective design, the effect of prophylaxis was studied. 
Availability of records to document, or reliably assess, the type and frequency of bleeding 
episodes prior to, and after, the initiation of prophylaxis was required. Annualized bleeding rates 
were calculated for the period prior to prophylaxis, during prophylaxis and by primary bleeding 
indication defined as the site accounting for more than half of all bleeding symptoms. The 
Wilcoxon signed-rank test of differences in the medians was used. Sixty-one subjects from 20 
centres in 10 countries were enrolled. Data for 59 were used in the analysis. The median age at 
onset of prophylaxis was 22.4 years. Type 3 VWD accounted for the largest number (N = 34, 
57.6%). Differences in bleeding rates within individuals during compared with before prophylaxis 
were significant for the total group (P < 0.0001), and for those with primary bleeding indications 
of epistaxis (P = 0.0005), joint bleeding (P = 0.002) and GI bleeding (P = 0.001). The effect of 
prophylaxis was similar among those age < 18 years and those ≥18. One person developed an 
inhibitor during treatment. We conclude that prophylactic treatment of VWD is efficacious.
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Introduction
von Willebrand’s disease (VWD) is the most common bleeding disorder [1], and is caused 
by quantitative (types 1 and 3) or qualitative (types 2A, 2B, 2M, 2N) defects of von 
Willebrand factor (VWF) [2]. Type 1 is the most prevalent form, affecting approximately 
55–70% of those with symptomatic disease [3]. Type 3, the most severe form of VWD, is 
rare, estimated to affect from 0.1 to 5.3 per million of the population [4,5]. The bleeding 
patterns of severe VWD adversely affect short- and long-term quality of life [6,7], and may 
be life threatening. The index case of VWD, described by Erik von Willebrand in 1926, was 
a girl who had a history of serious bleeds involving mucous membranes and ankle joints [8]. 
She subsequently died during her fourth menstrual period.
Clinically, the leading symptom in VWD is bleeding, chiefly of mucosal origin, e.g. 
epistaxis, gingival or GI bleeding and heavy menstrual bleeding. In the most serious forms 
of VWD, characterized by reduced levels of VWF activity measured as ristocetin cofactor 
(VWF:RCo <10 U dL−1) and of FVIII:C (<20 U dL−1), joint and muscle bleeding 
resembling that seen in mild or moderate haemophilia A may also be observed. Strategies 
for treatment vary by type and severity, and include DDAVP (desmopressin acetate), use of 
antifibrinolytics and therapy with VWF-containing concentrates to replace the VWF protein 
that is missing and/or abnormal [9].
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It is logical to translate the success of prophylaxis in haemophilia to severe VWD. 
Prophylaxis can be implemented early in life in a home setting, and prevention of bleeding 
and its consequences is possible [10,11]. The documented experience with long-term 
prophylaxis in VWD, however, is limited. In a Swedish multicentre study of subjects with 
VWF:RCo <8% and FVIII:C <10%, 37 were on long-term prophylaxis and 13 were treated 
on demand [12]. The study showed that those beginning prophylaxis at a young age (less 
than 5 years) had few or no bleeding episodes, and none had clinical signs of arthropathy or 
reported joint bleeding. Subjects beginning prophylaxis at >15 years of age usually reported 
a substantial reduction in joint bleeding, but had clinical and radiological signs of joint 
disease. Prophylaxis led to reductions in other types of bleeding, including epistaxis. The 
investigators concluded that long-term prophylactic treatment in VWD is warranted in the 
majority of cases with type 3, and in some cases, depending on the clinical phenotype, for 
those with other types of VWD. Similar conclusions were reached in another retrospective 
study performed in a small cohort of Italian patients [13]. Halimeh and colleagues have also 
reported on the use of secondary prophylaxis, finding a significant decrease in bleeding 
frequency [14].
The von Willebrand Disease Prophylaxis Network (VWD PN) was formed to investigate the 
role of prophylaxis in clinically severe VWD requiring use of VWF-containing concentrates 
due to lack of response to DDAVP or other treatments. In a network-sponsored survey of 74 
treatment centres conducted in 2005–2006, investigators reported that approximately 70% of 
their patients with type 3 VWD had been treated with VWF-containing plasma-derived 
products in the previous 12 months, and 22% were on prophylaxis. Use of prophylaxis for 
patients with type 1 and type 2 VWD was rare; the most commonly cited reasons for 
initiating prophylaxis were joint bleeding (40%), epistaxis/oral bleeding (23%), 
gastrointestinal (GI) bleeding (14%) and menorrhagia (5%) [15].
The VWD International Prophylaxis (VIP) study, which contains both retrospective and 
prospective study components, is an initiative of the VWD PN. The current report highlights 
results from a retrospective study of the effect of prophylaxis on bleeding frequency.
Materials and methods
Population
To be eligible, subjects must have been on a prophylactic regimen for VWD that was 
initiated at least 6 months prior to enrolment, or have a history of prophylaxis use for a 
period of at least 6 months that was subsequently discontinued because it was no longer 
required. Availability of records to document, or reliably assess, the type and frequency of 
bleeding episodes prior to, and after, the initiation of prophylaxis was required. Subjects 
were excluded if, in the judgment of the investigator, the subject had a history of non-
compliance with his or her treatment regimen. Data were collected between 2008 and 2011. 
The human-subjects committees of collaborating institutions approved the VIP study in 
compliance with the guidelines of the Declaration of Helsinki. The VIP study is registered at 
www.ClinicalTrials.gov.
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Patients were diagnosed locally at their centres. Variables collected included subject 
demographics, VWD type, site and frequency of bleeding episodes prior to, and after, the 
initiation of prophylaxis, and whether an inhibitor to VWF had ever been detected. Bleeding 
history was derived from centre records or registries, diaries and logs. Records were 
available for every bleeding episode during the period of study for nine (15%) participants. 
For all others, the investigator made an assessment of available documentation to determine 
the average number of bleeding episodes that occurred each month, and the distribution of 
the sites of bleeding. The primary indication for prophylaxis was defined as the bleeding 
symptom accounting for one half or more of a subject’s bleeding episodes. For four subjects 
the percentages were unknown, so a primary indication could not be identified. Other 
variables collected included the usual dose (U VWF:RCo per kg) per infusion during 
prophylaxis, and number of infusions administered per week or per menstrual cycle.
Statistical methods
Annualized bleeding rates were calculated for the periods prior to prophylaxis and during 
prophylaxis. For those participants with complete bleeding records, this was done by 
dividing the number of bleeding episodes by the duration of the period(s) of interest (prior 
and during) in years. For those whose records did not capture every bleed, either prior to or 
during prophylaxis, the reported number of bleeding episodes per month was multiplied by 
12. Annualized bleeding rates were calculated for the primary indication by multiplying the 
total annual number of bleeds by the proportion that occurred at the primary indication site. 
Medians and interquartile ranges (IQR) are used to describe bleeding rates. In addition, a 
‘paired’ approach was used to calculate the percent change in number of bleeding episodes 
within individuals by subtracting the number of bleeds that occurred before prophylaxis 
from the number of bleeds after prophylaxis, then dividing by the number of bleeds that 
occurred before prophylaxis. A paired Wilcoxon signed-rank test of the differences in the 
medians was used to compare the bleed rate overall and by primary indication.
Results
Sixty-one subjects from 20 treatment centres in 10 countries located in Europe (67%) and 
North America (33%) were enrolled. One patient was excluded because there were no 
records to reliably evaluate the type and frequency of bleeding episodes prior to the onset of 
prophylaxis. Among those with type 3 VWD, one patient had a history of an inhibitor 
diagnosed during childhood, a number of years prior to the onset of prophylaxis, and had 
been on prophylaxis for a period of just over 1 year. Testing conducted 2 months prior to 
enrolment in the current study showed an inhibitor concentration of 1 Bethesda Unit (BU). 
This patient was excluded from the analysis. A second subject was diagnosed with an 
inhibitor during prophylaxis and the regimen was subsequently discontinued. Data for this 
subject were used for the period prior to the detection of the inhibitor. Thus, the current 
analysis was completed with data for 59 subjects.
The median age (range) of subjects at start of prophylaxis was 22.4 (2.3–77.2). Age at start 
varied considerably by the indication for prophylaxis. For example, for those whose 
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bleeding was primarily epistaxis, the median age at start was 6.9 years, whereas for those 
with GI bleeding it was 55.8. The median period of time on prophylaxis was 2.2 years. 
Duration was somewhat longer, but not significantly so, among subjects from centres in 
Europe, median of 3.4 years, compared with centres in North America, median of 2.1 years. 
Other demographic and VWD-related characteristics of the study group are shown in Table 
1 Male and female subjects were represented almost equally. The vast majority of subjects 
were of European descent, with smaller proportions of participants of Hispanic, Asian, 
African descent and other races. Type 3 VWD accounted for the largest number: 34 
(57.6%).
Table 2 summarizes, by bleeding indication, characteristics for the study group including 
frequency of bleeding before and during prophylaxis; usual dose in U VWF:RCo/kg and the 
median number of infusions during prophylaxis. Overall, the median (IQR) rate of bleeding 
episodes in the year prior to prophylaxis was 12 (6–24), compared with a median (IQR) rate 
of 3.6 (0.96–9.4) during prophylaxis. In the case of occurrences of heavy menstrual 
bleeding, the changes represent a reduction in the number of days or intensity of bleeding 
with each cycle. In the year prior to prophylaxis, the median number of cycles in which 
heavy menstrual bleeding was reported was 12, compared with four per year during 
prophylaxis.
While Table 2 presents the median numbers of bleeding episodes before and after 
prophylaxis for the group overall, perhaps more meaningful are the percent reductions 
within individuals that occurred during the period of evaluation (Fig. 1). Differences in 
annualized bleeding rates within individuals (during prophylaxis – before prophylaxis) were 
significant for the total group (P < 0.0001), and for those with primary indications of 
epistaxis (P = 0.0005), joint bleeding (P = 0.002) and GI bleeding (P = 0.001), and of 
borderline significance (P = 0.055), for those in the category of ‘other’ indications. The 
within-individual difference in the group whose primary indication for treatment was 
abnormally heavy bleeding at menstruation (n = 4) was not significant (P = 0.25).
When we examined the effect of prophylaxis by age for subjects <18 (n = 26), and those ≥18 
(n = 33), we found that it was similar in both groups. The median within-individual number 
of bleeds per year after prophylaxis compared with before was significantly lower, P < 
0.0001 in both groups. A primary indication of joint bleeding occurred somewhat more 
frequently among those <18; however, GI bleeding and menorrhagia were not reported as 
the primary bleeding indication for prophylaxis for any subjects in that age group. Epistaxis 
was almost twice as likely to be the primary indication for prophylaxis among those <18 
compared with those aged ≥18 years (32.0% vs. 16.7%).
While the specifics of individual bleeding episodes were not available for all bleeds in the 
year prior to and following onset of prophylaxis, a total of 604 bleeds were reported. Of 
these, 529 (87.6%) were treated with a VWF-containing concentrate. The most commonly 
used products were Humate P, 77.1% (CSL Behring GmbH); Fandhi, 16.5% (Grifols); and 
Alphanate, 4.5% (Grifols).
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A review of reasons for inpatient and outpatient hospitalizations, and supplemental 
comments on study data collection forms revealed no reports of thrombotic events among 
those in the study group.
Discussion and conclusions
The data presented provide support for the use of long-term prophylaxis with VWF-
containing concentrates in cases of VWD that are not responsive to other treatments. The 
benefits of prophylaxis in haemophilia have been demonstrated repeatedly. Prevention of 
bleeding and arthropathy [10,11], better quality of life [16,17], fewer school absences and 
higher academic achievement in young school-age children have been documented [18]. 
Importantly, children with VWD in a Swedish cohort who started prophylaxis early never 
developed joint disease [12].
A few additional investigations have been reported using different VWF-containing 
concentrates [19,20], [21,22]. Common among these was the finding that prophylaxis 
appears to be effective at decreasing or eliminating bleeding, and that side effects are mild. 
No cases of thromboembolism have been reported. In the Swedish cohort, one patient 
developed an inhibitor. In a recent publication from Germany, a retrospective study of 32 
patients was reported. Following a 12-month period, the monthly bleeding frequency was 
significantly reduced compared with the preprophylaxis values (3 vs. 0.07), and an inhibitor 
developed in one patient.
Allo-antibodies against VWF are a rare complication of treatment with plasma-derived 
concentrates containing VWF [23]. They usually occur in type 3 VWD characterized by 
large deletions of the VWF gene; however, there are currently no data regarding the clinical 
and molecular markers of these complications. In particular, there is no evidence that 
prophylaxis with VWF concentrates triggers their appearance as in almost all cases reported, 
the antibodies developed during on-demand treatment.
In this study, the effect of prophylaxis appeared to be most pronounced in the case of joint 
bleeding, as has been observed in other investigations [12]. Joint haemorrhage occurs when 
FVIII levels are low. Haemarthroses are prevented primarily by the increase in FVIII levels 
during prophylaxis and not impacted by the VWF levels, per se. Mucosal bleeding, i.e. 
epistaxis, GI bleeding and menorrhagia, was reduced but not to the same degree, perhaps 
because these haemorrhages are not only dependent on normal circulating levels of active 
VWF, but also on the presence of discrete concentrations of normal VWF inside the platelets 
and within endothelial matrices. These considerations of the biology and physiopathology of 
VWF should be kept in mind when therapeutic approaches are chosen to stop or prevent 
mucosal bleeding, especially in patients with VWD types 3 or 2A, which are characterized 
by absent or abnormal VWF in platelet and endothelial sites.
In ex vivo experiments, the lack of normal platelet VWF was reported to be the major factor 
for impaired platelet adhesion to subendothelium in patients with VWD types 3 and 2A [24]. 
More importantly, when patients with VWD type 3 were given large doses of 
cryoprecipitate containing all the VWF multimers, all could correct VWF:RCo whereas 60% 
still showed prolonged bleeding time (BT), the surrogate marker of the cellular defect of 
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VWF at the vascular sites. A complete correction of BT could be obtained only when 
normal platelet concentrates were given after cryoprecipitate [25].
The fact that BT cannot always be normalized by exogenous VWF, despite the complete 
correction of circulating VWF:RCo and/or the intact multimeric structure of VWF in the 
concentrates, was clearly confirmed in a crossover randomized trial in type 3 VWD patients 
using four concentrates with different VWF and FVIII content [26]. Our results of a more 
modest resolution of mucosal bleeding during prophylaxis with VWF-containing 
concentrates, therefore, may not be surprising. Further investigation of response to 
prophylaxis by bleeding indication and VWD type requires a larger sample size, and is a 
planned topic of future exploration for the VIP study.
Epistaxis is frequent in haemostatically normal subjects, especially children, indicating that 
mechanisms in addition to the haemostatic system are involved. Gastrointestinal bleeding is 
known to be severe and difficult to treat in VWD, especially among patients with type 2 
disease [12]. The results in this study corroborate the findings of the few other published 
reports in the field, with higher doses used for that indication. Frequency of infusions and 
dosages reported were quite similar in our study compared to other studies. Determination of 
dose for prophylactic treatment of VWD has relied on prophylaxis in haemophilia as a 
template. Whether or not this is optimal has not been investigated. In the prospective 
component of the VIP study, participants undergo an escalation of treatment from one to 
three doses of VWF concentrate per week [15] with the objective of establishing optimal 
treatment regimens for joint bleeding, GI bleeding, epistaxis and menorrhagia.
No occurrence of thromboembolism was reported as a reason for inpatient or outpatient 
hospitalization. In fact, thromboembolism is rare in VWD [27,28] and the higher levels of 
FVIII/VWF obtained during prophylaxis are of short duration, probably explaining why 
these patients do not appear to be at high risk even though FVIII and VWF are both 
considered to be risk factors for venous thromboembolism.
Previous studies of prophylaxis in VWD have been limited to examination of data from a 
small number of haemophilia treatment centres. A major strength of this investigation is that 
it is multicentre with standardized data collection conducted in 20 centres across 10 
countries in Europe and North America. The number of patients with type 3 VWD (n = 34) 
was substantially higher than in other reports of prophylaxis in VWD, and the number of 
patients with type 2 VWD (n = 20) was greater as well. Results were generally consistent 
across bleeding indications and even age groups. The weakness of many retrospective 
studies, including this investigation, is that data collection depends on the ability to reliably 
assess or document, from varying sources, the occurrence of bleeding. As a requirement for 
participation in the VIP study, subjects must have been on prophylaxis for at least 6 months, 
and have demonstrated compliance with their regimen. While this may bias the study group 
by removing from observation those for whom prophylaxis was abandoned because of lack 
of success or acceptability, it nonetheless encourages continued evaluation, both 
retrospective and prospective.
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We conclude from this international, multicentre cohort study that prophylactic treatment of 
VWD is efficacious. This appears to be most evident in FVIII-dependent haemorrhages. A 
network-initiated prospective study is underway to confirm these findings, and address 
issues of cost-effectiveness and quality of life.
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Outcomes measured as percent reduction in bleeding within individuals during prophylaxis, 
according to primary indication for treatment.
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Table 1
Demographic and von Willebrand’s disease (VWD)-related characteristics (N = 59).
N (%)
Gender
 Female 28 (47.5)
 Male 31 (52.5)
Race/ethnicity
 White 43 (72.9)
 Hispanic 9 (15.3)
 Asian 5 (8.5)
 African descent 1 (1.7)
 Other 1 (1.7)
VWD type
 1 5 (8.5)
 2A 10 (17.0)
 2B 8 (13.6)
 2M 2 (3.4)
 2N 0 (0.0)
 3 34 (57.6)
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